• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

August 23, 2022

Continued Disparities Related to Age, Sex, Race, Ethnicity, Socioeconomic Status Exist in COVID-19 Booster Uptake

Author(s):

Lindsey Mulrooney

Less than half of fully vaccinated individuals in the United States have received a COVID-19 booster dose, with lower uptake rates among individuals with less education, lower socioeconomic status, and current enrollment in Medicaid.

With only 48.5% of those who had been fully vaccinated nationwide having received a booster dose and significant disparities among geographic, occupational, and sociodemographic groups, COVID-19 booster uptake is low, according to a study recently published in JAMA Network Open. Continued disparities exist, as boosted individuals were more likely than non-boosted individuals to be male, Asian, more educated, have a higher income level, older, live in the Northeast, and work in hospitals.

Though the CDC recommends that all individuals 12 years of age or older receive a COVID-19 mRNA vaccine booster dose 5 months after completion of an initial vaccination series, not all eligible individuals receive their booster vaccines. Researchers conducted a study to describe the geographic, occupational, and sociodemographic variations in uptake of COVID-19 booster doses among fully vaccinated US adults.

“Understanding geographic, occupational, and sociodemographic differences in receipt of booster doses among the fully vaccinated population can help inform targeted efforts to increase coverage,” they wrote.

The cross-sectional survey study sourced data from the Household Pulse Survey conducted from December 1, 2021, to January 10, 2022. The Household Pulse Survey is an online, probability-based survey conducted by the US Census Bureau, designed to yield estimates nationally, by state, and across selected metropolitan areas. A total of 135,821 adults completed the survey.

The survey found that 48.5% of those who had been fully vaccinated nationwide had received a booster dose (state-specific range, from 39.1% in Mississippi to 66.5% in Vermont). Variations were seen across geographic locations, occupation types, and other sociodemographic characteristics.

Nationally, the proportion of boosted adults was highest among non-Hispanic Asian individuals (54.1%); those 65 years of age or older (71.4%); those with a doctoral, professional, or master’s degree (68.1%); those who were married with no children in the household (61.2%); those with annual household income of $200,000 or higher (69.3%); those enrolled in Medicare (70.9%); and those working in hospitals (60.5%) or in deathcare facilities (eg, funeral homes; 60.5%). Conversely, the survey indicated that only one-third of those who ever received a diagnosis of COVID-19, were enrolled in Medicaid, working in pharmacies, with less than a high school education, and aged 18 to 24 years were boosted.

However, booster coverage widely varied even for workers in the same industry. Within health care facilities nationwide, booster coverage was nearly 25 percentage points higher among those working in hospitals compared with those working in a pharmacy, despite similar rates of initial vaccination completion.

The authors suggest that this variability in the uptake of booster doses reflects the greater volition in individuals’ decision to receive the vaccine, in contrast to the initial vaccination series for which mandates existed in many settings.

Fully vaccinated individuals who were also COVID-19 survivors had a 30% lower likelihood of getting a booster dose compared with those with no history of SARS-CoV-2 infection, suggesting that the perception of low susceptibility to COVID-19 or perceived protection from infection-induced immunity may explain relatively low uptake of booster doses, according to the study authors.

The survey found that uninsured individuals were significantly less likely to receive a booster dose compared with those with insurance. Individuals reporting financial difficulties had half the booster coverage of those reporting no financial difficulty.

Booster coverage was also observed to decrease with less education. Booster coverage was double among those with a doctoral, professional, or master’s degree than those with less than a high school education.

These findings indicated that socioeconomic barriers may limit uptake of booster doses, despite the vaccine being free in the United States. The authors note that scheduling a visit, getting time from work, getting transportation, or overcoming language barriers may be some of these barriers.

They recommend providing mobile vaccination clinics within low-income neighborhoods on a walk-in basis and launching multilingual awareness campaigns as a potential method to benefit public health. Overall, they suggest that intensified efforts to increase coverage of booster doses may benefit public health by averting excess premature morbidity and mortality from COVID-19.

The study has some limitations, including a cross-sectional design that means only associations, not causation, can be inferred. The design also prevented researchers from teasing apart age, period, and cohort effects, including timing of diagnosis and vaccination. Therefore, they were unable to determine whether people got boosted in response to having been infected or got infected despite having been boosted.

Additionally, the proportion of boosted individuals among the subpopulation of immunocompromised individuals may have been overestimated. The CDC recommends that individuals who are immunocompromised should receive a third primary dose, and the researchers were unable to discriminate between a third dose that was a primary dose or a booster; however, the magnitude of this bias is likely small.

Reference

Agaku I T, Adeoye C, Long T G. Geographic, occupational, and sociodemographic variations in uptake of COVID-19 booster doses among fully vaccinated us adults, December 1, 2021, to January 10, 2022. JAMA Netw Open. 2022;5(8):e2227680. doi:10.1001/jamanetworkopen.2022.27680. Published August 19, 2022. Accessed August 19, 2022.

Related Videos
Image credit: Dr_Microbe | stock.adobe.com
Image credit: K KStock | stock.adobe.com
Image credit: komokvm | stock.adobe.com
Vial of Pneumococcal vaccine - Image credit: Bernard Chantal | stock.adobe.com
Related Content
Advertisement
Illustration of myocardial infarction
May 30th 2025

NLA 2025: Inclisiran With Standard Care Provides Rapid, Sustained Lowering of LDL-C in Patients With Recent Acute Coronary Syndrome

Luke Halpern, Assistant Editor
Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings
May 28th 2025

Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings

Alexandra Gerlach, Associate Editor
Woman can't eat bread and grain products because of gluten intolerance. A young celiac woman suffers from abdominal pain after eating fresh bread - Image credit: weyo | stock.adobe.com
May 30th 2025

FDA Grants Fast Track Designation to Drug Candidate for Celiac Disease

Kennedy Ferruggia, Assistant Editor
Pharmacy Focus: Navigating Seasonal Allergies
May 28th 2025

Pharmacy Focus: Navigating Seasonal Allergies

Luke Halpern, Assistant Editor Derek Webb, PharmD
TKIs binding to target proteins | Image Credit: © Justlight - stock.adobe.com
May 30th 2025

Patient Reported Outcomes Show Improved Symptoms With Zongertinib for HER2-Mutated Non-Small Cell Lung Cancer

Alexandra Gerlach, Associate Editor
NLA 2025: The Complementary Roles of ANGPTL3 and ANGPTL4 in Lipid Regulation and Therapy
May 30th 2025

NLA 2025: The Complementary Roles of ANGPTL3 and ANGPTL4 in Lipid Regulation and Therapy

Sander Kersten, PhD Alana Hippensteele, Lead Editor
Related Content
Advertisement
Illustration of myocardial infarction
May 30th 2025

NLA 2025: Inclisiran With Standard Care Provides Rapid, Sustained Lowering of LDL-C in Patients With Recent Acute Coronary Syndrome

Luke Halpern, Assistant Editor
Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings
May 28th 2025

Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings

Alexandra Gerlach, Associate Editor
Woman can't eat bread and grain products because of gluten intolerance. A young celiac woman suffers from abdominal pain after eating fresh bread - Image credit: weyo | stock.adobe.com
May 30th 2025

FDA Grants Fast Track Designation to Drug Candidate for Celiac Disease

Kennedy Ferruggia, Assistant Editor
Pharmacy Focus: Navigating Seasonal Allergies
May 28th 2025

Pharmacy Focus: Navigating Seasonal Allergies

Luke Halpern, Assistant Editor Derek Webb, PharmD
TKIs binding to target proteins | Image Credit: © Justlight - stock.adobe.com
May 30th 2025

Patient Reported Outcomes Show Improved Symptoms With Zongertinib for HER2-Mutated Non-Small Cell Lung Cancer

Alexandra Gerlach, Associate Editor
NLA 2025: The Complementary Roles of ANGPTL3 and ANGPTL4 in Lipid Regulation and Therapy
May 30th 2025

NLA 2025: The Complementary Roles of ANGPTL3 and ANGPTL4 in Lipid Regulation and Therapy

Sander Kersten, PhD Alana Hippensteele, Lead Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Download on Apple
© 2025 MJH Life Sciences

All rights reserved.